Slide 1: 2023 Earnings Presentation
2023 - Earnings Presentation March 14, 2024
Slide 2: Disclaimer
Disclaimer Forward-looking statements are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its con
Slide 3: Sell-Out Growth of 6% in 2023!
Sell-Out Growth of 6% in 2023! MAIN FACTORS THAT AFFECTED THE SELL-OUT GROWTH 3%' sell-out reduction in Flu, Respiratory, Pain and Fever Worsening credit conditions for medium-sized chains and independent retailers throughout the year, especially in 4Q23 12%’ sell-out increase in categories not rela
Slide 4: Power Brands that accounted for 55% of Sales in 2023
25 Power Brands’ that accounted for 55% of Sales in 2023 $2 Power Brands added in 2023 vitaminas Quimica £& SIMPLEORGANIC 2 Colfle & Flavonid” Nesina’ Neosaldina TENGOV) Aliviurr Epocler PredSim Busg@pan - BENEGRIP += NEQSORO episol Busg@fem Histamin Doralgina Etameriney Lisador Torsilax Coristina c
Slide 5: 2023 Main Highlights
2023 Main Highlights lof? @ FTSE4Good IDIVB3 ISEB3 Around 90 new products launched in 2023 Part of the FTSE4Good Index Series, of the London Stock Exchange Part of B3's IDIVERSA Part of JSE B3 for the 2™ consecutive year Featured in the S&P Global Sustainability Yearbook for the 2"4 consecutive year
Slide 6: 2023 Results (R$ million)
6 2023 Results (R$ million) ww Ww Ww WH WY VY > NET REVENUE RS$7,914.7 +4.9%' (4023: R$1,846.9 -12.9%!) GROSS MARGIN 63.1%? +0bps! (4023: 62.1%? -20bps’) MARKETING EXPENSES 15.7%? +10bps! (4023: 15.8%? +160bps’) SELLING EXPENSES 11.7%? +100bps' (4023: 13.0%? +200bps') GENERAL AND ADMINISTRATIVE EXPE
Slide 7: Gross Cash, Cash Flow and Net Debt at end of 2023
Gross Cash at Cash Flow from PP&E Intangibles 2023 Free Cash Cash Flow from Interest on Gross Cash at Gross Debt at Net Debt at the the end of 2022 Operations Flow Financing Capital the end of 2023 the end of 2023 end of 2023
Slide 8: Final Considerations
Final Considerations AA Market growth and Hypera Pharma's Sell-Out' growth All recovery in the first two months of 2024 { Financial Objectives for 2024: - Net Revenue around R$8.6 billion - EBITDA from Continuing Operations around R$3.0 billion - Net Profit from Continuing Operations around R$1.85 b
Slide 9: Hypera Pharma's Strengths
Hypera Pharma's Strengths "a >) >) 0 1B) peze) NN. , - - Wn) Ars )- Kk Se z Ls = _— 4 Irreplicable portfolio Present in 97%? Brazil's largest Pipeline with of leading brands, of the drugstores manufacturing 500+ Projects including 25 Power in Brazil complex in the Brands’ pharmaceutical LL market J)
Slide 10: Slide 10